| Added by | pcoopman |
|---|---|
| Last modified by | standudu |
| Group name | EquipePC |
| Item Type | Journal Article |
| Title | Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study |
| Creator | Heudel et al. |
| Author | Pierre Heudel |
| Author | Suzette Delaloge |
| Author | Damien Parent |
| Author | Nicolas Madranges |
| Author | Christelle Levy |
| Author | Florence Dalenc |
| Author | Etienne Brain |
| Author | Lionel Uwer |
| Author | Paule Augereau |
| Author | Audrey Mailliez |
| Author | Christophe Perrin |
| Author | Marie-Paule Sablin |
| Author | Marie-Ange Mouret-Reynier |
| Author | Thomas Vermeulin |
| Author | Jean-Christophe Eymard |
| Author | Thierry Petit |
| Author | Jean-Marc Ferrero |
| Author | Silvia Ilie |
| Author | Anthony Goncalves |
| Author | GaËlle Chenuc |
| Author | Mathieu Robain |
| Abstract | BACKGROUND/AIM: Vinorelbine is indicated for use in the treatment of MBC as a single agent or in combination but there is little real world data on this molecule and even less on its oral form. We exploited the Unicancer Epidemiology Strategy Medical-Economics (ESME) metastatic breast cancer (MBC) database to investigate current patterns of use of oral vinorelbine (OV), as well as outcomes of patients receiving this drug. PATIENTS AND METHODS: Data were collected retrospectively from women and men treated for MBC between 2008 and 2014 at one of 18 French Comprehensive Cancer Centres. The efficacy of OV was evaluated in terms of progression-free (PFS) and overall survival (OS) and treatment duration. The population and patterns of OV usage were also described. RESULTS: A total of 1806 patients (11% of the ESME MBC database) were included in this analysis. OV was prescribed as monotherapy (46%) or in combination (29%), especially with capecitabine. mainly in later treatment lines. Median PFS was 3.3 months: 2.9 months for single agent, 3.6 months for combination therapy. Median OS was 40.9 months. CONCLUSION: Real-world data offer complementary results to the data from traditional clinical trials, but they concern a much larger population. In this ESME MBC cohort, OV was only prescribed to a small subset of MBC patients. OV was mainly given as single agent to patients with heavily pre-treated MBC; less commonly, it was co-administered with capecitabine or anti-HER2, in earlier lines of therapy. PFS was modest but in line with previous reports. |
| Publication | Anticancer Research |
| Volume | 40 |
| Issue | 7 |
| Pages | 3905-3913 |
| Date | Jul 2020 |
| Journal Abbr | Anticancer Res. |
| Language | eng |
| DOI | 10.21873/anticanres.14381 |
| ISSN | 1791-7530 |
| Short Title | Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer |
| Library Catalog | PubMed |
| Extra | 00000 PMID: 32620631 |
| Tags | clinic, ESME, metastatic breast cancer, retrospective study, Vinorelbine |
| Date Added | 2020/07/17 - 17:57:41 |
| Date Modified | 2020/10/04 - 14:01:57 |
| Notes and Attachments | PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
